Method for the early detection of renal disease using proteomics
A method for the detection of an early biomarker for assessing a change in renal status in a mammalian subject following a renal event. The method typically includes the steps of (a) providing a body fluid sample obtained from a mammalian subject; (b) analyzing the molecular weight of the proteins in the sample using proteome analysis; and (c) identifying the presence of a protein in the sample selected from the group consisting of a 6.4 kDa protein, a 28.5 kDa protein, a 33 kDa protein, a 44 kDa protein, a 67 kDa protein, and combinations thereof. The presence of one of these proteins can serve as an early biomarker for assessing a change in renal status. The levels of these proteins can be compared to predetermined levels, and thus provide a determination of the subject's renal status. The invention also includes a method of assessing the administration of aprotinin during cardio-pulmonary bypass surgery and provides for methods where the level of the 6.4 kDa biomarker in the subject's urine directs a caregiver's therapeutic decision regarding the intra-operative administration of aprotinin.
1. A method for the detection of an early biomarker for assessing acute renal failure (ARF) following a renal event, the method comprising the steps of:
a. analyzing the molecular weight of the proteins in a body fluid sample obtained from a mammalian subject following a renal event using proteome analysis; and
b. identifying the presence of a combination of proteins consisting of a 6.4 kDa protein, a 28.5 kDa protein, a 33 kDa protein, a 44 kDa protein, and a 67 kDa protein, the presence of the combination serving as an early biomarker for assessing a change in renal status.
2. The method of claim 1 , wherein the body fluid for the sample is selected from the group consisting of urine, blood, serum, plasma, saliva, lymph, cerebrospinal fluid, cystic fluid, ascites, stool, bile, and any other isolatable body fluid.
3. The method of claim 1 , wherein the body fluid for the sample is isolated urine.
4. The method of claim 1 , wherein proteome analysis is accomplished by the SELDI-TOF-MS technique.
5. The method of claim 1 , wherein the protein is a 6.4 kDa protein.
6. The method of claim 1 , wherein the protein is a plurality of proteins consisting of a 28.5 kDa protein, a 33 kDa protein, a 44 kDa protein, and a 67 kDa protein.
7. The method of claim 1 , wherein the combination consists of a 33 kDa protein, a 67 kDa protein and combinations thereof.
8. A method for determining acute renal injury of a mammalian subject within 48 hours following a renal event, the method comprising the steps of:
a. separating the proteins in a body fluid sample obtained from a mammalian subject at a time within 48 hours following a renal event by molecular weight using proteome analysis;
b. identifying a combination of separated proteins based on the molecular weight of the separated protein, the combination consisting of a 6.4 kDa protein, a 28.5 kDa protein, a 33 kDa protein, a 44 kDa protein, and a 67 kDa protein; and
c. comparing the level of each identified protein to a predetermined level thereof, the comparison providing a determination of the subject's renal status.
9. The method of claim 8 , wherein the separated protein is a plurality of proteins consisting of a 28.5 kDa protein, a 33 kDa protein, a 44 kDa protein, and a 67 kDa protein.
10. The method of claim 8 , wherein the body fluid for the sample is selected from the group consisting of urine, blood, serum, plasma, saliva, lymph, cerebrospinal fluid, cystic fluid, ascites, stool, bile, and any other isolatable body fluid.
11. The method of claim 8 , wherein the body fluid for the sample is isolated urine.
12. The method of claim 8 , wherein proteome analysis is accomplished by the SELDI-TOF-MS technique.